Consolidated Balance Sheets - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 20,157,692	$ 26,043,897
Licensing, contracts and grants receivable	321,779	138,889
Research and development incentives receivable	109,017	103,832
Prepaid expenses and other current assets	237,135	282,903
Total current assets	20,825,623	26,569,521
Security deposit	22,777	22,777
Office furniture and equipment, net of accumulated depreciation of $106,948 and $167,848	26,299	22,220
Deferred issuance cost	20,266	20,266
Right-of-use lease assets	393,226	106,155
Research and development incentives receivable	24,263	121,238
Other assets		7,750
Total assets	21,312,454	26,869,927
Current liabilities:
Accounts payable	4,141,006	2,925,544
Accrued expenses	2,437,596	2,956,545
Accrued compensation	57,762	302,936
Lease liabilities - current	103,949	106,151
Convertible debt, current	2,000,000
Deferred revenue, current	100,000
Total current liabilities	8,840,313	6,291,176
Non-current liabilities:
Convertible debt, net of current portion and debt discount of $123,249 and $143,847	7,876,751	9,856,153
Lease liabilities, net of current portion	289,504
Deferred revenue, net of current portion	100,000
Total liabilities	17,106,568	16,147,329
Commitments and contingencies
Shareholders' equity:
Preferred stock, 350,000 shares authorized; none issued or outstanding
Common stock, $.001 par value; 75,000,000 shares authorized; 43,050,245 shares and 42,873,445 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively	43,050	42,873
Additional paid-in capital	216,652,655	216,402,890
Accumulated other comprehensive income	11,069	41,942
Accumulated deficit	(212,500,888)	(205,765,107)
Total shareholders' equity	4,205,886	10,722,598
Total liabilities and shareholders' equity	$ 21,312,454	$ 26,869,927